HIMS & HERS HEALTH INC

FTC slaps Hims & Hers Health with a sweeping lawsuit over deceptive billing, hidden subscriptions, and unauthorized data sharing—watch how this legal storm reshapes the telehealth sector.

Hims & Hers Health secures $400 M receivables facility from JPMorgan, boosting liquidity for its expanding telehealth platform and investor confidence.

Hims & Hers Health’s telehealth platform is reshaping U.S. care, but its sharp stock volatility and negative P/E raise investor concerns—what’s next for this tech‑driven health innovator?

Hims & Hers stock surges 10% ahead of May 11 earnings, analysts expect $0.03 EPS and a post‑earnings range of $22–$30, driving growth in telehealth & pharma partnerships.

Hims & Hers stock soars 30% after FDA peptideregulation lift, BPC‑157 boost and Bank of America upgrade—telehealth’s next growth engine revealed.

Hims & Hers shares jump 7% after settling with Novo Nordisk to sell Wegovy and Ozempic, boosting its weight‑loss arm and analyst upgrades – but oil‑price volatility cautions investors.

Hims & Hers Health partners with Novo Nordisk to distribute weight‑loss meds via its telehealth platform, sparking a 20% stock surge and new growth prospects.

Hims & Hers partners with Novo Nordisk to distribute Wegovy, boosting its health‑tech reach, stock, and investor confidence amid FDA scrutiny and a 40% share surge.

Hims & Hers stock drops 70% after FDA pulls its copy‑cat weight‑loss drug and Novo Nordisk sues for patent infringement, exposing the company’s legal and growth risks.

Hims & Hers Health’s latest investor moves, ETF yields, and platform growth reveal a robust telehealth trajectory despite short‑seller focus.